sot101,srf388,nemvaleukin alfa,modakafusp alfa
sotio,alkermes,takeda,surface oncology
['nemvaleukin', 'srf388 ', 'sot101 ', 'modakafusp']
early phase trials of novel cytokine-based therapies, including nemvaleukin alfa (il-2/cd25 fusion), srf388 (anti-il-27), sot101 (il-15 superagonist) &amp; modakafusp alfa (anti-cd38/ifn fusion), reported at #asco22. read more about such approaches here: 
The latest clinical diagnostic, treatment & personalized medicine advances & more from Nature Reviews Clinical Oncology, a reviews journal. Tweets by the eds.